Pradaxa Shines On Strength Of Results, But Panelists Wary Of Future Trials With Similar Design
This article was originally published in The Pink Sheet Daily
Executive Summary
Boehinger Ingelheim's dabigatran eked out a unanimous endorsement from FDA's Cardio-Renal Advisory Committee, but the panel had concerns about the potential for bias from the open-label trial design.
You may also be interested in...
FDA Plays It Safe With Boehringer Ingelheim's Pradaxa By Approving A Single Dosing Option
Regulators accept bleeding risk for superiority over warfarin, staying away from a temptingly safer but less effective dabigatran dose.
FDA Plays It Safe With Boehringer Ingelheim's Pradaxa By Approving A Single Dosing Option
Regulators accept bleeding risk for superiority over warfarin, staying away from a temptingly safer but less effective dabigatran dose.
FDA's Pradaxa Quandary: Clearing Both Doses Could Mask Dabigatran's Superiority
The pivotal issue remaining for FDA's review of Boehringer Ingelheim's Pradaxa (dabigatran) is whether it will clear both the 110 mg and 150 mg doses and how it can craft labeling to guide appropriate use toward the higher dose, which seems likely to gain a superiority claim over warfarin.